litlas
Log inCreate account

Sandy Srinivas

Active 1995–2025

95
Papers
21,007
Citations
58
h-index
90
i10-index

Citations

Citations per year for Sandy Srinivas1997: 4 citations1998: 3 citations1999: 3 citations2000: 1 citations2001: 5 citations2002: 3 citations2003: 5 citations2004: 8 citations2005: 8 citations2006: 8 citations2007: 6 citations2008: 19 citations2009: 18 citations2010: 23 citations2011: 32 citations2012: 48 citations2013: 63 citations2014: 96 citations2015: 95 citations2016: 137 citations2017: 285 citations2018: 326 citations2019: 885 citations2020: 1,000 citations2021: 936 citations2022: 611 citations2023: 558 citations2024: 1,048 citations2025: 475 citations2026: 16 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,714 citing papers, 25% of this breakdownChina: 1,126 citing papers, 10.4% of this breakdownItaly: 668 citing papers, 6.1% of this breakdownUnited Kingdom: 628 citing papers, 5.8% of this breakdownGermany: 544 citing papers, 5% of this breakdownFrance: 517 citing papers, 4.8% of this breakdownCanada: 486 citing papers, 4.5% of this breakdownSpain: 381 citing papers, 3.5% of this breakdownJapan: 344 citing papers, 3.2% of this breakdownNetherlands: 310 citing papers, 2.8% of this breakdownAustralia: 296 citing papers, 2.7% of this breakdownSwitzerland: 261 citing papers, 2.4% of this breakdown
0%25%Other 23.8%

Institutions

Fields

  • Medicine83.9%
  • Biochemistry, Genetics and Molecular Biology9.4%
  • Immunology and Microbiology3.1%
  • Engineering0.9%
  • Computer Science0.7%
  • Economics, Econometrics and Finance0.2%
  • Other1.8%

Topics

  • Cancer Immunotherapy and Biomarkers11.2%
  • Prostate Cancer Treatment and Research7.3%
  • Bladder and Urothelial Cancer Treatments7.1%
  • Prostate Cancer Diagnosis and Treatment5.8%
  • Renal cell carcinoma treatment4.7%
  • Ferroptosis and cancer prognosis2.8%
  • Other61.1%

Coauthors

All papers

Open in search
  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    Authors: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 cited by 3,714

  2. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    Authors: Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman‐Censits, José Luis Perez‐Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Ignacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 cited by 2,211

  3. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

    Authors: Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel A. Barocas, Rhonda L. Bitting, Alan H. Bryce, Brian F. Chapin, Heather H. Cheng, Anthony V. D’Amico, Neil Desai, Tanya B. Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael Kuettel, Joshua M. Lang, Tamara L. Lotan, Rana R. McKay, Todd M. Morgan, George J. Netto, Julio M. Pow‐Sang, Robert E. Reiter, Mack Roach, Tyler P. Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan D. Tward, Richard K. Valicenti, J.K. Wong, Dorothy A. Shead, Jenna Snedeker, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2023 cited by 571

  4. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

    Authors: Christopher Hoimes, Thomas W. Flaig, Matthew I. Milowsky, Terence W. Friedlander, Mehmet Asım Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R. Merchan, Rana R. McKay, Daniel P. Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne‐Sophie Carret, Jonathan E. Rosenberg - Journal of Clinical Oncology 2022 cited by 267

  5. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

    Authors: Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, David C. Smith, Dean Ruether, Thomas W. Flaig, Joaquina Baranda, Joshua M. Lang, Elizabeth R. Plimack, Randeep Sangha, Elisabeth I. Heath, Jamie Merchan, David I. Quinn, Sandy Srinivas, Matthew I. Milowsky, Chunzhang Wu, Elaina M. Gartner, Peiying Zuo, Amal Melhem‐Bertrandt, Daniel P. Petrylak - Journal of Clinical Oncology 2020 cited by 327

  6. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    Authors: Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar, Helen Moon, Terence W. Friedlander, Rana R. McKay, Mehmet Asım Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, J.P. Maroto Rey, Christiano Ferrario, Anne‐Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg - Journal of Clinical Oncology 2023 cited by 175

  7. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis

    Authors: Han Zhu, Francisco X. Galdos, Daniel Lee, Sarah Waliany, Yuhsin Vivian Huang, Julia Ryan, Katherine Dang, Joel W. Neal, Heather A. Wakelee, Sunil Reddy, Sandy Srinivas, Lih‐Ling Lin, Ronald Witteles, Holden T. Maecker, Mark M. Davis, Patricia K. Nguyen, Sean M. Wu - Circulation 2022 cited by 174

  8. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

    Authors: Edward M. Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather H. Cheng, Anthony V. D’Amico, Brian J. Davis, Neil Desai, Tanya B. Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric M. Horwitz, Joseph E. Ippolito, Michael Kuettel, Joshua M. Lang, Rana R. McKay, Jesse K. McKenney, George J. Netto, David F. Penson, Julio M. Pow‐Sang, Robert E. Reiter, Sylvia Richey, Mack Roach, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan D. Tward, Dorothy A. Shead, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2021 cited by 530

  9. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann S. de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Simon Chowdhury, Caroline S. Clarke, Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  10. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

    Authors: James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya B. Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael E. Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael Kuettel, Joshua M. Lang, Jesse K. McKenney, George J. Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow‐Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach, Stan Rosenfeld, Edward M. Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan D. Tward, Dorothy A. Shead, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2019 cited by 1,573

  11. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Joseph E. Burgents, Lei Xu, Kentaro Imai, David I. Quinn, Toni K. Choueiri, Piotr Tomczak, Toni K. Choueiri, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Jaroslav Hájek, Tzu-Ping Lin, Stefan N. Symeonides, Jae‐Lyun Lee, Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz and 133 more - The Lancet Oncology 2022 cited by 278

  12. Prostate Cancer, Version 3.2024

    Authors: Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Rhonda L. Bitting, Brian F. Chapin, Heather H. Cheng, Anthony V. D’Amico, Neil Desai, Tanya B. Dorff, James A. Eastham, Thomas A. Farrington, Xīn Gào, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, R. Jeffrey Karnes, Michael Kuettel, Joshua M. Lang, Tamara L. Lotan, Rana R. McKay, Todd M. Morgan, Julio M. Pow‐Sang, Robert E. Reiter, Mack Roach, Tyler P. Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Russell Z. Szmulewitz, Benjamin A. Teply, Jonathan D. Tward, Richard K. Valicenti, J.K. Wong, Jenna Snedeker, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2024 cited by 272

  13. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.

    Authors: Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel A. Barocas, Rhonda L. Bitting, Alan H. Bryce, Brian F. Chapin, Heather H. Cheng, Anthony V. D’Amico, Neil Desai, Tanya B. Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael Kuettel, Joshua M. Lang, Tamara L. Lotan, Rana R. McKay, Todd M. Morgan, George J. Netto, Julio M. Pow‐Sang, Robert E. Reiter, Mack Roach, Tyler P. Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan D. Tward, Richard K. Valicenti, J.K. Wong, Ryan A. Berardi, Dorothy A. Shead, Deborah A. Freedman-Cass - 2022 cited by 172

  14. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

    Authors: Thomas Powles, Peter H. O’Donnell, Christophe Massard, Hendrik-Tobias Arkenau, Terence W. Friedlander, Christopher Hoimes, Jae‐Lyun Lee, Michael Ong, Srikala S. Sridhar, Nicholas J. Vogelzang, Mayer Fishman, Jingsong Zhang, Sandy Srinivas, Jigar Parikh, Joyce Antal, Xiaoping Jin, Ashok Gupta, Yong Ben, Noah M. Hahn - JAMA Oncology 2017 cited by 846

  15. Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors

    Authors: Sarah Waliany, Joel W. Neal, Sunil Reddy, Heather A. Wakelee, Sumit Shah, Sandy Srinivas, Sukhmani K. Padda, Alice C. Fan, A. Dimitrios Colevas, Sean M. Wu, Ronald Witteles, Han Zhu - JACC CardioOncology 2021 cited by 118

  16. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann S. de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Simon Chowdhury, Caroline S. Clarke, Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  17. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

    Authors: Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh, Min Yuen Teo, Randy F. Sweis, Daniel M. Geynisman, Petros Grivas, Gurkamal Chatta, Zachery R. Reichert, Joseph W. Kim, Mehmet Asım Bilen, Bradley A. McGregor, Parminder Singh, Abhishek Tripathi, Suzanne Cole, Nicholas I. Simon, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Sandy Srinivas, Jiaoti Huang, Meagan Odegaard, Colleen Watt, Daniel P. Petrylak, Jeannie Hoffman-Censits, Yujia Wen, Olwen Hahn, Cecilia Mitchell, Alan W.C. Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J. Morris, Jonathan E. Rosenberg - New England Journal of Medicine 2024 cited by 145

  18. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Authors: Sumanta K. Pal, Bradley McGregor, Cristina Suárez, Che-Kai Tsao, William Kelly, Ulka Vaishampayan, Lance Pagliaro, Benjamin L. Maughan, Yohann Loriot, Daniel Castellano, Sandy Srinivas, Rana R. McKay, Robert Dreicer, Thomas Hutson, Sarita Dubey, Scott Werneke, Ashok Panneerselvam, Dominic Curran, Christian Scheffold, Toni K. Choueiri, Neeraj Agarwal - Journal of Clinical Oncology 2021 cited by 140

  19. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

    Authors: Hossein Jadvar, Jérémie Calais, Stefano Fanti, Felix Y. Feng, Kirsten L. Greene, James L. Gulley, Michael S. Hofman, Bridget F. Koontz, Daniel W. Lin, Michael J. Morris, Steve P. Rowe, Trevor J. Royce, Simpa S. Salami, Bital Savir-Baruch, Sandy Srinivas, Thomas A. Hope - Journal of Nuclear Medicine 2021 cited by 143

  20. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)

    Authors: Neeraj Agarwal, Bradley A. McGregor, Benjamin L. Maughan, Tanya B. Dorff, William Kevin Kelly, Bruno Fang, Rana R. McKay, Parminder Singh, Lance C. Pagliaro, Robert Dreicer, Sandy Srinivas, Yohann Loriot, Ulka N. Vaishampayan, Sanjay Goel, Dominic Curran, Ashok Panneerselvam, Martin Schwickart, Toni K. Choueiri, Sumanta K. Pal - The Lancet Oncology 2022 cited by 66

  21. Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Authors: Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea Harzstark, Ronald M. Bukowski, Brian I. Rini, Sandy Srinivas, Mark N. Stein, Laurel M. Adams, Lone H. Ottesen, Kevin Laubscher, Laurie Sherman, David F. McDermott, Naomi B. Haas, Keith T. Flaherty, Robert W. Ross, Peter D. Eisenberg, Paul S. Meltzer, Maria J. Merino, Donald P. Bottaro, W. Marston Linehan, Ramaprasad Srinivasan - Journal of Clinical Oncology 2012 cited by 458

  22. Prostate Cancer, Version 1.2016

    Authors: James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Anthony V. D’Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael E. Hurwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Joshua J. Meeks, David F. Penson, Elizabeth R. Plimack, Julio M. Pow‐Sang, David Raben, Sylvia Richey, Mack Roach, Stan Rosenfeld, Edward M. Schaeffer, Ted A. Skolarus, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Seth A. Strope, Jonathan D. Tward, Dorothy A. Shead, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2016 cited by 655

  23. PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer

    Authors: Lucia Baratto, Hong Song, Heying Duan, Negin Hatami, H.P. Bagshaw, Mark K. Buyyounouski, Steven Hancock, Sumit Shah, Sandy Srinivas, Patrick S. Swift, Farshad Moradi, Guido Davidzon, Andrei Iagaru - Journal of Nuclear Medicine 2021 cited by 66

  24. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma

    Authors: Sumanta K. Pal, Guru Sonpavde, Neeraj Agarwal, Nicholas J. Vogelzang, Sandy Srinivas, Naomi B. Haas, Sabina Signoretti, Bradley A. McGregor, Jeremy O. Jones, Richard B. Lanman, Kimberly C. Banks, Toni K. Choueiri - European Urology 2017 cited by 142